KATHLEEN I. PRITCHARD, M.D., F.R.C.P.(C); J. WILLIAM MEAKIN, M.D., F.R.C.P.(C); ROBERT E. MYERS, M.D., F.R.C.P.(C); DONALD J. A. SUTHERLAND, M.D., F.R.C.P.(C); BETTY G. MOBBS, PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: A recent article by Legha, Davis, and Muggia (Ann Intern Med 88:69-77, 1978) documents the effectiveness of tamoxifen in postmenopausal women with metastatic breast cancer but refers to only one report of its use in premenopausal women (1). Other reports have documented its use only occasionally in premenopausal women (2-5). We report here the preliminary results of a phase II trial of tamoxifen in premenopausal women with metastatic breast cancer.
Thirty premenopausal patients with measurable metastatic breast cancer who had received no prior hormonal manipulation were given tamoxifen, 40 mg daily, in two divided doses. Of the
PRITCHARD KI, MEAKIN JW, MYERS RE, SUTHERLAND DJA, MOBBS BG. Tamoxifen and Metastatic Breast Cancer. Ann Intern Med. ;89:721–722. doi: 10.7326/0003-4819-89-5-721_2
Download citation file:
© 2019
Published: Ann Intern Med. 1978;89(5_Part_1):721-722.
DOI: 10.7326/0003-4819-89-5-721_2